Hope vs. Power: Gene Therapy, FDA Shake-Up, and Truth in Medicine — The Doctors’ Lounge

🎯 Why Listen

When hope collides with billion-dollar incentives, who protects patients? We unpack Vinay Prasad’s FDA resignation, Sarepta’s $3.2M Duchenne gene therapy, and how accelerated approvals can leave families without the long-term data they deserve.

👥 Co-Hosts

Dutch Rojas – Founder, Bliksem Health
Anthony DiGiorgio, DO, MHA – Neurosurgeon, UCSF; health policy researcher
Anish Koka, MD – Cardiologist, Philadelphia; healthcare policy commentator
Dan Choi, MD, FAAOS – Orthopedic spine surgeon, Long Island; healthcare advocate and social media voice
Sanat Dixit, MD, FACS – Neurosurgeon, Huntsville, AL; Faculty, Vanderbilt University; healthcare entrepreneur

📌 Episode Overview

Vinay Prasad’s exit from FDA/CBER and what it signals about evidence, safety, and politics.
Duchenne muscular dystrophy, Sarepta’s one-shot gene therapy, and deaths linked to vector toxicity.
The promise and peril of accelerated approvals—and why confirmatory trials so often stall.
Left vs. right myths about healthcare; markets, incentives, and why “healthcare is a right” can fail in practice.
Quick hits: public-good economics in medicine, decentralization vs. central control, and where AI may actually help (RCM, workflow).

💬 Notable Quotes

“These trials are never gonna get done. It’s a game—with patients as pawns.”
“The FDA is the Midas touch: approval turns hope into revenue—fast.”
“You don’t want a world where healthcare is non-excludable and non-rivalrous.”
“If healthcare is ‘first, do no harm,’ who decides what harm looks like—and who pays the price?”

📚 What You’ll Learn

How accelerated approval works—and where it breaks.
Why safety signals (e.g., vector-related liver failure) matter more than press releases.
The difference between hope, evidence, and incentives in rare disease.
How political tribes systematically misunderstand healthcare mechanics.
Practical places AI can improve care operations today.

⏱ The Episode (Timestamps)

00:00–01:10 Welcome back & cadence update (new Sunday drops)
01:10–07:40 Vinay Prasad resigns from FDA/CBER—context and stakes
07:40–13:30 Duchenne 101, dystrophin biology, trial endpoints vs. real outcomes
13:30–17:30 Accelerated approval promises vs. missing confirmatory trials
17:30–22:30 Safety signals: vector immunogenicity, reported deaths, what pulls look like
22:30–28:30 Media/influencer pressure and the politics of “right to try”
28:30–41:30 Is healthcare a public good? Scarcity, incentives, and economic reality
41:30–50:30 Government, morality, and why central planning fails patients
50:30–59:30 AI, agents, and near-term wins in physician workflows
59:30–End What we need next from policymakers—and from clinicians

🔗 Connect with the Hosts:

• Dutch Rojas on X

• Dr. Anthony DiGiorgio on X

• Dr. Anish Koka on X

• Dr. Dan Choi on X

• Dr. Sanat Dixit on X

🔗 Connect with the Hosts:

• Dr. Anthony DiGiorgio on X

• Dr. Anish Koka on X

• Dr. Dan Choi on X

• Dr. Sanat Dixit on X